
Alaunos Therapeutics Investor Relations Material
Latest events

Q1 2023
Alaunos Therapeutics

Q1 2025
9 Jul, 2025

Q4 2024
30 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Alaunos Therapeutics Inc
Access all reports
Alaunos Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer treatment. The company specializes in T-cell receptor (TCR) therapies, leveraging its proprietary Sleeping Beauty non-viral gene transfer platform to engineer T-cells that target solid tumors with specific genetic mutations. Alaunos’s pipeline targets a range of cancers, including lung, ovarian, and pancreatic cancers. The company is headquartered in Houston, Texas, and its shares are listed on the NASDAQ.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
TCRT
Country
🇺🇸 United States